Advanced search
Publication Cover
Future Oncology Volume 20, 2024 - Issue 8
Submit an article Journal homepage
1,350
Views
0
CrossRef citations to date
0
Altmetric
Short Communication

Matching-Adjusted Indirect Comparison of Amivantamab vs Mobocertinib in Platinum-Pretreated EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer

Tae Min Kim1 Hemato-Oncology and Medical Oncology Center, Seoul National University Hospital, Seoul, 03080, KoreaORCID Iconhttps://orcid.org/0000-0001-6145-4426
ORCID Icon,
Nicolas Girard2 Medical Oncology, Institut Curie, Institut du Thorax Curie-Montsouris, Paris cedex 05, 75248, France
,
Natasha B Leighl3 Cancer Clinical Research Unit, Princess Margaret Cancer Centre, Toronto, Ontario, M5G 2M9, Canada
,
Joshua Sabari4 Medical Oncology, New York University Langone Health, New York, NY 10016, USA
,
Nora Rahhali5 Janssen Cilag, Île-de-France, 92787, France
,
Claudio A Schioppa6 Janssen Pharmaceutica NV, Beerse, B-2340, Belgium
,
Joris Diels6 Janssen Pharmaceutica NV, Beerse, B-2340, Belgium
,
Jan Sermon6 Janssen Pharmaceutica NV, Beerse, B-2340, Belgium
,
Conor Chandler7 Evidence Synthesis, Modeling & Communication, Evidera, Waltham, MA 02451, USA
,
Venediktos Kapetanakis8 Evidence Synthesis, Modeling & Communication, Evidera, London, W6 8BJ, UK
,
Ruhee Jain9 Janssen R&D, Raritan, NJ 08869, USA
,
Tracy Li9 Janssen R&D, Raritan, NJ 08869, USA
&
Suzy Van Sanden6 Janssen Pharmaceutica NV, Beerse, B-2340, BelgiumCorrespondence[email protected]
 show all
Pages 447-458 | Received 19 Jul 2023, Accepted 15 Sep 2023, Published online: 26 Oct 2023

References

  • Van Sanden S, Murton M, Bobrowska Aet al. Prevalence of Epidermal Growth Factor Receptor Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer in Europe: A Pragmatic Literature Review and Meta-analysis. Target Oncol. 17(2), 153–166 (2022).
  • American Lung Association . EGFR and Lung Cancer. www.lung.org/lung-health-diseases/lung-disease-lookup/lung-cancer/symptoms-diagnosis/biomarker-testing/egfr (Accessed 22 March 2022 ).
  • Wang F, Li C, Wu Q, Lu H. EGFR exon 20 insertion mutations in non-small-cell lung cancer. Transl. Cancer Res. 9(4), 2982–2991 (2020).
  • Vyse S, Huang PH. Targeting EGFR exon 20 insertion mutations in non-small-cell lung cancer. Signal Transduct. Target Ther. 4, 5 (2019).
  • Bazhenova L, Minchom A, Viteri Set al. Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations. Lung Cancer 162, 154–161 (2021).
  • Kwon CS, Lin HM, Crossland Vet al. Non-small-cell lung cancer with EGFR exon 20 insertion mutation: a systematic literature review and meta-analysis of patient outcomes. Curr. Med. Res. Opin. 38(8), 1341–1350 (2022).
  • Park K, Haura EB, Leighl NBet al. Amivantamab in EGFR Exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS Phase I study. J. Clin. Oncol. 39(30), 3391–3402 (2021).
  • Vadagam P, Vanderpoel J, Khan Aet al. Estimated Costs of Adverse Event Management in NSCLC Patients with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations Treated with Amivantamab or Mobocertinib after Progression on Platinum-Based Chemotherapy. Value in Health. 25(6 Suppl. 1), EE274 (2022).
  • RYBREVANT™ (amivantamab-vmjw) [package insert]. Janssen Biotech, Inc, Horsham, PA (2021).
  • Zhou C, Ramalingam SS, Kim TMet al. Treatment outcomes and safety of mobocertinib in platinum-pretreated patients With EGFR exon 20 insertion-positive metastatic non-small-cell lung cancer: a Phase I/II open-label nonrandomized clinical trial. JAMA Oncol. 7(12), e214761 (2021).
  • National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) . NCCN Guidelines V.3.2022 Non-Small Cell Lung Cancer.© National Comprehensive Cancer Network, Inc. 2022. All rights reserved. www.nccn.org/ (Accessed 20 February 2023 ).
  • Ou S-HI, Prawitz T, Lin HMet al. Matching-adjusted indirect comparison (MAIC) of mobocertinib versus amivantamab in patients with non-small-cell lung cancer (NSCLC) with EGFR exon 20 insertions (ex20ins). J. Clin. Oncol. 40(Suppl. 16), 9115 (2022).
  • Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med. Res. Methodol. 12, 9 (2012).
  • Russell MC, Garelli AM, Reeves DJ. Targeting EGFR Exon 20 insertion mutation in non-small-cell lung cancer: amivantamab and mobocertinib. Ann. Pharmacother. 57(2), 198–206 (2022).
  • Janne P, Wang M, Mitchell Pet al. OA15.02 Phase I studies of DZD9008, an oral selective EGFR/HER2 inhibitor in advanced NSCLC with EGFR exon20 insertion mutations. J. Thorac. Oncol. 16(10), S874 (2021).
  • Yang J-H, Wang M, Mitchell Pet al. Preliminary safety and efficacy results from phase I studies of DZD9008 in NSCLC patients with EGFR exon20 insertion mutations. J. Clin. Oncol. 39(Suppl. 15), 9008 (2021).
  • Yu HA, Tan DS-W, Smit EFet al. Phase (Ph) 1/2a study of CLN-081 in patients (pts) with NSCLC with EGFR exon 20 insertion mutations (Ins20). J. Clin. Oncol. 40(Suppl. 16), 9007 (2022).
  • Van Der Weijst L, Surmont V, Schrauwen W, Lievens Y. 171P Association between patient-reported toxicity and health-related quality of life in (locally-) advanced non-small-cell lung cancer. J. Thorac. Oncol. 16, S791–S792 (2021).
  • Van Sanden S, Rahhali N, Schioppa Cet al. Matching-Adjusted Indirect Comparison of Amivantamab vs. Mobocertinib in EGFR Exon 20 Insertion-Mutated non-small-cell Lung Cancer. Value in Health. 25(6_S1), MSR41 (2022).
  • Minchom AR, Krebs MG, Cho BCet al. Subcutaneous amivantamab (ami) in patients (pts) with advanced solid malignancies: the PALOMA study-Updated safety and identification of the recommended phase 2 dose. J. Clin. Oncol. 41, 9126 (2023).

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.